Study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in...
Dr Zev Wainberg - University of California Los Angeles, California, USA
Study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic oesophageal cancer ( Dr Zev Wainberg - University of California Los Angeles, California, USA )
12 Jul 2021
Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or ...
Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA
Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer ( Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA )
14 Jun 2021
Pembrolizumab improves on chemo in MSI-H/dMMR mCRC
Prof Thierry André - Sorbonne University and Saint-Antoine Hospital, Paris, Fran...
Pembrolizumab improves on chemo in MSI-H/dMMR mCRC ( Prof Thierry André - Sorbonne University and Saint-Antoine Hospital, Paris, France )
11 Jun 2021
CHRONOS: Anti-EGFR rechallenge therapy with panitumumab driven by ctDNA molecula...
Prof Andrea Sartore-Bianchi - Ospedale Niguarda, Milan, Italy
CHRONOS: Anti-EGFR rechallenge therapy with panitumumab driven by ctDNA molecular selection in mCC ( Prof Andrea Sartore-Bianchi - Ospedale Niguarda, Milan, Italy )
10 Jun 2021
Tislelizumab in oesophageal cancer after systemic therapy
Dr Jaffer Ajani - The University of Texas MD Anderson Cancer Center, Texas, USA
Tislelizumab in oesophageal cancer after systemic therapy ( Dr Jaffer Ajani - The University of Texas MD Anderson Cancer Center, Texas, USA )
9 Jun 2021
OncoAlert and ecancer ASCO roundup - Day 3
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer ASCO roundup - Day 3 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
8 Jun 2021
PANAMA: Maintenance 5FU/LV plus panitumumab or 5FU/LV alone in RAS wildtype mCRC
Prof Dominik Modest - Charité Universitätsmedizin Berlin, Berlin, Germany
PANAMA: Maintenance 5FU/LV plus panitumumab or 5FU/LV alone in RAS wildtype mCRC ( Prof Dominik Modest - Charité Universitätsmedizin Berlin, Berlin, Germany )
8 Jun 2021
OncoAlert and ecancer ASCO roundup - Day 2
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer ASCO roundup - Day 2 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
8 Jun 2021
OncoAlert and ecancer ASCO roundup - Day 1
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer ASCO roundup - Day 1 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
8 Jun 2021
Bemarituzumab with FOLFOX6 in FGFR2b+ advanced gastric/gastroesophageal junction...
Prof Daniel Catenacci - University of Chicago, Chicago, USA
Bemarituzumab with FOLFOX6 in FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma ( Prof Daniel Catenacci - University of Chicago, Chicago, USA )
5 Jun 2021
Incidence and trends of HPV-related cancers in the United States
Dr John Chan - UCSF Helen Diller Family Comprehensive Cancer Center, San Francis...
Incidence and trends of HPV-related cancers in the United States ( Dr John Chan - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )
4 Jun 2021
OncoAlert and ecancer weekly roundup for April 19 - 25, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly roundup for April 19 - 25, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
26 Apr 2021